Document ID: chunk:federal_register_of_legislation:F2024L01391:schedule:1
Version: federal_register_of_legislation:F2024L01391
Segment Type: schedule
Provision Reference: sch 1
Character Range: 2478–3945

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)
     1.            Schedule 3, after entry for Morphine in the form Tablet containing morphine sulfate pentahydrate 20 mg
    insert:
Morphine  Tablet containing morphine sulfate pentahydrate 30 mg

     1.            Schedule 4, entries for Estradiol
    substitute:
Estradiol  Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28
Estradiol  Transdermal patches 390 micrograms, 8
Estradiol  Transdermal patches 585 micrograms, 8
Estradiol  Transdermal patches 585 micrograms, 24 (S19A)
Estradiol  Transdermal patches 780 micrograms, 8
Estradiol  Transdermal patches 780 micrograms, 24 (S19A)
Estradiol  Transdermal patches 1.17 mg, 8
Estradiol  Transdermal patches 1.17 mg, 24 (S19A)
Estradiol  Transdermal patches 1.56 mg, 8
Estradiol  Transdermal patches 1.56 mg, 24 (S19A)
Estradiol  Transdermal patches 750 micrograms (as hemihydrate), 8
Estradiol  Transdermal patches 1.5 mg (as hemihydrate), 8
Estradiol  Transdermal patches 3 mg (as hemihydrate), 8

     1.            Schedule 4, entry for Naloxone
    omit:
Naloxone  Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 (s19A)

     1.            Schedule 4, after entry for Timolol in the form Eye drops 5 mg (as maleate) per mL, 5mL
    insert:
Timolol  Eye drops 5 mg (as maleate) per mL, 5 mL (S19A)